AIHTA - Publications - Search - Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)

Grössmann, N. (2021): Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Oncology Fact Sheet Nr. 41.

[thumbnail of Oncology Fact Sheet Nr.41.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
74kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 440-468 Uterine diseases
Language:English
Series Name:Oncology Fact Sheet Nr. 41
Deposited on:24 Mar 2021 16:50
Last Modified:24 Mar 2021 16:50

Repository Staff Only: item control page